Image

North America IgA Nephropathy Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Oct 2021
  • North America
  • 350 Pages
  • No of Tables: 81
  • No of Figures: 49

North America IgA Nephropathy Market, By Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Symptoms (Haematuria, Proteinuria, Edema, and Others), Type (Diagnosis and Treatment), Population Type (Paediatrics and Adults), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028. 

North America IgA Nephropathy Market

 

Market Analysis and Insights: North America IgA Nephropathy Market

North America IgA nephropathy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 19.7% in the forecast period of 2021 to 2028 and is expected to reach USD 451.40 million by 2028 from USD 126.49 million in 2020. The increasing drug discoveries for IgA nephropathy are the major drivers that drive the market demand in the forecast period. The rise in IgA nephropathy disorder increases disease burden, increasing the demand for diagnosis and treatment products, thus driving the North America IgA nephropathy market growth.

IgA nephropathy, also known as Berger's disease, is a kidney disease caused by the build-up of IgA deposits in the kidneys, which cause inflammation and damage to the kidney tissues. Antibodies such as IgA are proteins produced by the immune system to shield the body from foreign substances, including bacteria and viruses. The complication of this disease is the ESKD which then needs dialysis for treatment.

The increasing IgA nephropathy targeted pipeline drugs allows the potential candidate to show the efficacy for IgA nephropathy treatment hence acts as a driver for the IgA nephropathy market. The cost of treatment of IgA nephropathy increases patients' pocket burden if reimbursement is absent, hence acting as a restraint for the IgA nephropathy market growth. Collaboration of market players for drug development increases the presence and innovation, hence acting as an opportunity for the IgA nephropathy market growth. Side effects associated with the treatment of IgA nephropathy and the COVID-19 impact on the immunosuppressive drugs market pose a challenge for the growth of the IgA nephropathy market.

The North America IgA nephropathy market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the IgA nephropathy market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.

North America IgA Nephropathy Market North America IgA Nephropathy Market Scope and Market Size

North America IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the North America IgA nephropathy market is segmented into primary IgA nephropathy and secondary IgA nephropathy. In 2021, the primary IgA nephropathy segment is expected to dominate the market because the incidence of primary IgA nephropathy is more and can be diagnosed by blood or urine test easily.
  • On the basis of symptoms, the North America IgA nephropathy market is segmented into haematuria, proteinuria, edema, and others. In 2021, the haematuria segment is expected to dominate the market as it is the most common and frequently used parameter for clinical examination and is detected by the amount of blood in the urine showing the occurrence of disease in the kidney.
  • On the basis of type, the North America IgA nephropathy market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market because prior given the treatment, the proper detection, and tracing of the IgA nephropathy is necessary. It is possible only through the primary detection such as blood and urine tests and confirmatory detection by kidney biopsy, which are the major factor of this segment.
  • On the basis of population type, the North America IgA nephropathy market is segmented into paediatrics and adults. In 2021, the adults segment is expected to show significant growth because the studies showed the connection of this disease with aging.
  • On the basis of route of administration, the North America IgA nephropathy market is segmented into oral, parenteral, and others. In 2021, the oral segment is expected to dominate the market due to the wide variety of oral product portfolios available in interstate commerce, which increases the market of this segment.
  • On the basis of end user, the North America IgA nephropathy market is segmented into hospitals, clinics, home healthcare, and others. In 2021, the hospitals segment is expected to dominate the market due to its strong financial structure.
  • On the basis of distribution channel, the North America IgA nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment accelerates revenue growth and provides tax benefits. The direct tender segment has been flourishing for the last few years, henceforth, affirmative illustrating the further growth of the market.

North America IgA Nephropathy MarketNorth America IgA Nephropathy Market Country Level Analysis

North America IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user, and distribution channel.  

The countries covered in the North America IgA nephropathy market report are the U.S., Canada, and Mexico.

North America is expected to dominate the market due to the rise in demand for IgA nephropathy by researchers and scientists in the region. The U.S. is dominating the market and leading the growth in the North America market due to the increased presence of key market players in the region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Acquisition and Merger is Creating New Opportunities for Players in the North America IgA Nephropathy Market

The North America IgA nephropathy market also provides you with a detailed market analysis for every country's growth. Additionally, it provides data regarding acquisition and agreement among the major market players and start-up companies. Moreover, the growing impact of research and development activities on the North America IgA nephropathy market growth pace. The data is available for the historical period 2010 to 2019.

Competitive Landscape and North America IgA Nephropathy Market Share Analysis

The North America IgA nephropathy market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus related to the North America IgA nephropathy market.

The major players covered in the North America IgA nephropathy report are AstraZeneca, Novartis AG, Pfizer Inc., Zydus Cadila, Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Hikma Pharmaceuticals PLC, LUPIN, Accord Health, Viatris Inc., Seimens Healthcare GmBH (a subsidiary of Seimens Healthineers AG), ARAKAY USA, Inc., Merck Sharp & Dohme. (a subsidiary of Merck & Co., Inc.), Strides Pharma Science Limited and Apotex Inc., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies worldwide, which accelerates the IgA nephropathy market.

For instance,

  • In March 2017, Apotex Inc. Announced that they had invested USD 184 Million in Investment to Grow U.S. Manufacturing Presence. This is the Expansion Plan Comprises Company's Largest Investment in the United States. This has increased the company manufacturing to meet the demand for the product

Collaboration, joint ventures, and other strategies by the market players enhance the company's impression in the North America IgA nephropathy market, which also benefits the organization to improve their IgA nephropathy sales growth.

Customization Available: North America IgA Nephropathy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 NORTH AMERICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 2 NORTH AMERICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 21 NORTH-AMERICA IGA NEPHROPATHY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 22 U.S. IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 23 U.S. IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 24 U.S. IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 25 U.S. DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 26 U.S. DIAGNOSIS BY URINE IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 27 U.S. TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 28 U.S. TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 29 U.S. TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 30 U.S. TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 31 U.S. TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 32 U.S. TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 33 U.S. IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 34 U.S. TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 35 U.S. TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 36 U.S. IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)

TABLE 37 U.S. IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 38 U.S. ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 39 U.S. PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 40 U.S. IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 41 U.S. IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 42 CANADA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 43 CANADA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 44 CANADA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 45 CANADA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 46 CANADA DIAGNOSIS BY URINE IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 CANADA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 CANADA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 CANADA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 CANADA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 CANADA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 CANADA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 53 CANADA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 CANADA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 55 CANADA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 CANADA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)

TABLE 57 CANADA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 58 CANADA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 59 CANADA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 60 CANADA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 61 CANADA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 62 MEXICO IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 63 MEXICO IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 64 MEXICO IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 MEXICO DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 MEXICO DIAGNOSIS BY URINE IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 MEXICO TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 MEXICO TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 69 MEXICO TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 70 MEXICO TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 71 MEXICO TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 72 MEXICO TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 73 MEXICO TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 74 MEXICO TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 MEXICO TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 MEXICO IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)

TABLE 77 MEXICO IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 78 MEXICO ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 79 MEXICO PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 80 MEXICO IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 MEXICO IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions